Study Title
177-Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (Lunar)
Study Details
Description:
This phase II trial tests whether 177-Lutetium-PSMA given before stereotactic body radiotherapy (SBRT) works to improve cancer control rate in patients with 1-5 prostate cancer tumors that have come back after prior treatment (oligorecurrent). Radioactive drugs, such as 177-Lutetium-PSMA, may carry radiation directly to tumor cells and not harm normal cells. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving 177-Lutetium-PSMA before SBRT may make the SBRT more effective.
Sponsor:
Jonsson Comprehensive Cancer Center (UCLA)
Contacts:
Rejah Marie Nabong (Clinical Research Manager)rmalano@mednet.ucla.edu
3102067372
Kiara Booker (Clinical Research Coordinator)kmbooker@mednet.ucla.edu
Government Study Link:
NCT05496959 - Click here to see study onClinicalTrials.gov
- Oligorecurrent prostate cancer as determined by the presence of 1-5 asymptomatic lesions outside the prostate or bed
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2
- Histologic confirmation of prostate adenocarcinoma (histology from original treatment acceptable)
- No indication for urgent or emergent radiation
- Patients who received androgen deprivation therapy within 6 months of trial enrollment
- Patients with castrate-resistant disease (i.e., PSA > 0.5 ng/mL with serum testosterone < 150 ng/dL)
- Concurrent systemic therapy for a solid organ malignancy
- Known hypersensitivity to components of 177Lu-PNT2002
- Patients with neuroendocrine or small cell carcinoma of the prostate
Patient Education
Patient Education Not Yet Provided
Publications
Locations
Not yet provided. Contact Rejah Marie Nabong for more information.
3102067372
rmalano@mednet.ucla.edu
